Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 287


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.


Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).

O'Brien EC, Simon DN, Roe MT, Wang TY, Peterson ED, Alexander KP.

Am J Cardiol. 2015 Jun 15;115(12):1655-60. doi: 10.1016/j.amjcard.2015.03.007. Epub 2015 Mar 23.


Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.

Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH; TNT Steering Committee and Investigators.

J Am Coll Cardiol. 2015 Apr 21;65(15):1539-48. doi: 10.1016/j.jacc.2015.02.017.


The new dyslipidemia guidelines: what is the debate?

Anderson TJ, Mancini GB, Genest J Jr, Grégoire J, Lonn EM, Hegele RA.

Can J Cardiol. 2015 May;31(5):605-12. doi: 10.1016/j.cjca.2014.11.007. Epub 2014 Nov 11. Review.


What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?

Santos RD.

Atheroscler Suppl. 2014 Sep;15(2):19-25. doi: 10.1016/j.atherosclerosissup.2014.07.003. Review.


Update on the NCEP ATP-III emerging cardiometabolic risk factors.

Eckel RH, Cornier MA.

BMC Med. 2014 Aug 26;12:115. doi: 10.1186/1741-7015-12-115. Review.


LDL cholesterol: controversies and future therapeutic directions.

Ridker PM.

Lancet. 2014 Aug 16;384(9943):607-17. doi: 10.1016/S0140-6736(14)61009-6. Review.


Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM.

Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004. Epub 2014 May 15.


Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.

Folse HJ, Goswami D, Rengarajan B, Budoff M, Kahn R.

Atherosclerosis. 2014 Sep;236(1):154-61. doi: 10.1016/j.atherosclerosis.2014.06.027. Epub 2014 Jul 7.


The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy.

Soran H, Schofield JD, Durrington PN.

Curr Opin Lipidol. 2014 Aug;25(4):239-46. doi: 10.1097/MOL.0000000000000097. Review.


Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets.

Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA.

Atherosclerosis. 2014 Aug;235(2):585-91. doi: 10.1016/j.atherosclerosis.2014.05.914. Epub 2014 May 22.


The roles of nitric oxide and hydrogen sulfide in the anti-atherosclerotic effect of atorvastatin.

Liu X, Ma D, Zheng S, Zha K, Feng J, Cai Y, Jiang F, Li J, Fan Z.

J Cardiovasc Med (Hagerstown). 2015 Jan;16(1):22-8. doi: 10.2459/JCM.0000000000000012.


Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.

Zambon A, Zhao XQ, Brown BG, Brunzell JD.

Am J Cardiol. 2014 May 1;113(9):1494-8. doi: 10.1016/j.amjcard.2014.01.426. Epub 2014 Feb 11.


A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.

Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr.

Cancer Prev Res (Phila). 2014 May;7(5):496-504. doi: 10.1158/1940-6207.CAPR-13-0189. Epub 2014 Mar 10.


The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.

Zhao SP, Yu BL, Peng DQ, Huo Y.

Atherosclerosis. 2014 Apr;233(2):707-12. doi: 10.1016/j.atherosclerosis.2013.12.003. Epub 2014 Jan 8.


Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S.

Clin Ther. 2014 Jan 1;36(1):58-69. doi: 10.1016/j.clinthera.2013.12.003.


Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.

White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators.

J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360.


Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.

Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K.

Circulation. 2014 Jan 7;129(1):77-86. doi: 10.1161/CIRCULATIONAHA.113.003625. Epub 2013 Oct 20.


Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.

Kim SH, Kim MK, Seo HS, Hyun MS, Han KR, Cho SW, Kim YK, Hoon Park S.

Clin Ther. 2013 Sep;35(9):1350-60.e1. doi: 10.1016/j.clinthera.2013.06.020. Epub 2013 Aug 30.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk